Verofylline

CAS No. 66172-75-6

Verofylline( —— )

Catalog No. M34733 CAS No. 66172-75-6

Verofylline (Verofyllinum) is an orally available, long-acting, multiacting, methylxanthine-substituted bronchodilator with inhibitory effects on PDE4 for the treatment of asthma disease research obesity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 333 In Stock
10MG 504 In Stock
25MG 816 In Stock
50MG 1097 In Stock
100MG 1479 In Stock
200MG Get Quote In Stock
500MG 2967 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Verofylline
  • Note
    Research use only, not for human use.
  • Brief Description
    Verofylline (Verofyllinum) is an orally available, long-acting, multiacting, methylxanthine-substituted bronchodilator with inhibitory effects on PDE4 for the treatment of asthma disease research obesity.
  • Description
    Verofylline (Verofyllinum) is an orally available, long-acting, multiacting, methylxanthine-substituted bronchodilator with inhibitory effects on PDE4 for the treatment of asthma disease research obesity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    66172-75-6
  • Formula Weight
    250.3
  • Molecular Formula
    C12H18N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C(CC)C)N1C2=C(C(=O)N(C)C1=O)NC(C)=N2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Tetomilast

    Tetomilast (OPC-6535) is a superoxide anion production inhibitor that inhibits PDE4 and proinflammatory functions.

  • PDE9-IN-(S)-C33

    PDE9-IN-(S)-C33 is a potent and selective inhibitor of PDE9 (IC50 = 11 nM). PDE9-IN-(S)-C33 can be used for central nervous system diseases and diabetes research.

  • Isomazole

    Isomazole is a novel orally available phosphodiesterase (PDE) inhibitor with calcium-sensitizing properties that inhibits PDE3 and PDE4.